About Our Company – ADC Therapeutics Learn about ADC Therapeutics, a commercial-stage oncology biotechnology company, leading the development of next-generation antibody drug conjugates (ADCs)
Antibody Drug Conjugates Clinical Development – ADC Therapeutics ADC Therapeutics is advancing a portfolio of investigational ADCs including those which utilize our highly potent pyrrolobenzodiazepine (“PBD”) technology, a differentiated exatecan-based payload with a novel hydrophilic linker and a next generation ADC toolbox
ADC Therapeutics Announces $100 Million Private Placement Extending . . . ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs) The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors
Investor Relations – ADC Therapeutics Latest news for ADC Therapeutics, a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation ADCs
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial . . . ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs) The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors
Press Releases – ADC Therapeutics ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
ADC Therapeutics Reports First Quarter 2025 Financial Results and . . . ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs) The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors